Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rna interference
alnylam pharmaceuticals
biotech
drugs
fda
national top stories
patisiran
san francisco blog main
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
aminolevulinic acid
arrowhead pharmaceuticals
barry greene
boehringer ingelheim
boston university
dan ollendorf
deals
dicerna pharmaceuticals
eli lilly
givosiran
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
john berk
johnson & johnson
mary o'donnell
neurodegenerative diseases
new york blog main
What
ago
3
×
rna
3
×
alnylam
fda
interference
medicine
rnai
abandoning
approval
approve
awaits
baggage
biological
companies
crossed
cuts
deal
decades
decision
development
dicerna
discovered
drug
fingers
free
friday
gets
historic
indicated
long
medicines
nod
patients
pharma
pharmaceuticals
quick
second
seek
signs
small
Language
Current search:
rna
×
ago
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
